Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Dade Behring PFA-100

This article was originally published in The Gray Sheet

Executive Summary

Dade Behring PFA-100: Firm receives FDA 510(k) clearance of its microprocessor-based, blood-platelet analyzer and disposable test cartridges for use in clinical labs to measure the ability of blood to clot during the first phase of hemostasis. The system requires an 800-microliter blood sample (about 16 drops) and delivers quantitative results in five to 10 minutes. Information obtained from the test "is particularly important for treating patients with abnormal bleeding caused by medication such as aspirin...or due to congenital conditions such as von Willebrand disease," the firm claims. Available in Europe since 1996, the test will complement other hemostasis products marketed by Dade Behring that measure the blood's clotting ability in the second phase of hemostasis...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts